Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications.
Plessier A, Esposito-Farèse M, Baiges A, Shukla A, Garcia Pagan JC, De Raucourt E, Ollivier-Hourmand I, Cervoni JP, De Ledinghen V, Tazi Z, Nousbaum JB, Bun R, Bureau C, Silvain C, Tournilhac O, Gerfaud-Valentin M, Durand F, Goria O, Tellez L, Albillos A, Gioia S, Riggio O, De Gottardi A, Payance A, Rautou PE, Terriou L, Charbonnier A, Elkrief L, de la Tour RP, Valla DC, Gault N, de Fontbrune FS. Plessier A, et al. Among authors: charbonnier a. Am J Hematol. 2022 Apr;97(4):431-439. doi: 10.1002/ajh.26474. Epub 2022 Jan 31. Am J Hematol. 2022. PMID: 35049058 Free article.
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
Devillier R, Bertoli S, Prébet T, Huguet F, Etienne A, Charbonnier A, Rey J, Delabesse E, D'Incan E, Huynh A, Blaise D, Récher C, Vey N. Devillier R, et al. Among authors: charbonnier a. Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25363834 Free article. No abstract available.
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N. Prebet T, et al. Among authors: charbonnier a. Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721 Free article.
Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
Devillier R, Gelsi-Boyer V, Murati A, Prebet T, Rey J, Etienne A, D'Incan E, Charbonnier A, Blaise D, Mozziconacci MJ, Vey N. Devillier R, et al. Among authors: charbonnier a. Am J Hematol. 2015 Jan;90(1):E22-4. doi: 10.1002/ajh.23850. Epub 2014 Oct 18. Am J Hematol. 2015. PMID: 25219760 Free article. No abstract available.
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive D. Vey N, et al. Among authors: charbonnier a. Blood. 2012 Nov 22;120(22):4317-23. doi: 10.1182/blood-2012-06-437558. Epub 2012 Sep 21. Blood. 2012. PMID: 23002117 Free article. Clinical Trial.
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE. Heiblig M, et al. Among authors: charbonnier a. Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5. Exp Hematol. 2018. PMID: 30195076 Free article.
Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines.
Marcault C, Venton G, Gastaud L, Mannone L, Rey J, D'Incan E, Saillard C, Charbonnier A, Raynaud S, Vey N, Cluzeau T. Marcault C, et al. Among authors: charbonnier a. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e76-e81. doi: 10.1016/j.clml.2019.11.016. Epub 2019 Nov 26. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31865004
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R, Harbi S, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Etienne A, Calmels B, Lemarie C, Prebet T, Granata A, Charbonnier A, Rey J, Chabannon C, Faucher C, Vey N, Blaise D. Devillier R, et al. Among authors: charbonnier a. Biol Blood Marrow Transplant. 2014 Oct;20(10):1560-5. doi: 10.1016/j.bbmt.2014.06.006. Epub 2014 Jun 14. Biol Blood Marrow Transplant. 2014. PMID: 24933658 Free article.
274 results